ENHERTU plus pertuzumab approved for first-line HER2+ metastatic breast cancer Dec 15, 2025 02:30PM
Daiichi Sankyo, AstraZeneca (AZN): ENHERTU Plus Pertuzumab Reduced the Risk of Disease Progression or Death Jun 2, 2025 08:06AM
IDeate-Esophageal01 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Certain Patients with Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma May 19, 2025 07:01AM